CBIO Brand Development Inc – Trademark Portfolio

Entity Type: 03

CBIO Brand Development Inc holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 9 filings in this category. The portfolio also extends into Class 34 (Smokers Articles) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include ARMOURGENIX. The owner is based in Vancouver, B.C..

Suite 1070

1055 West Hastings Street

Vancouver, B.C. V6E2E9 , CA

10 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

CBIO Brand Development Inc's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (9 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

34
Smokers Articles (1 filing)

Tobacco; smokers articles; matches

Frequently Asked Questions

How many trademarks does CBIO Brand Development Inc have?

CBIO Brand Development Inc has 10 U.S. trademarks filed with the USPTO. Of these, 1 registered, 9 abandoned.

What trademark classes does CBIO Brand Development Inc file in?

CBIO Brand Development Inc files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 34 (Smokers Articles). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are CBIO Brand Development Inc's most well-known trademarks?

CBIO Brand Development Inc's registered trademark portfolio includes well-known marks such as ARMOURGENIX. These are among 1 currently registered trademark in the portfolio.

What is CBIO Brand Development Inc's trademark registration success rate?

CBIO Brand Development Inc has a 10% trademark registration rate, with 1 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.